简介: [摘要 ] 目的 探讨乌司他丁在重症病毒性肺炎免疫调节治疗的临床疗效。 方法 回顾性分析 2017年 1月— 2019年 12月我院重症医学科收治的重症病毒性肺炎患者的临床资料,分析乌司他丁对患者免疫及预后的影响。结果 纳入 74例重症病毒性肺炎患者,死亡 19例( 25.7%) ;治疗组 36例,第 7天 CRP( 46.2±32.8) mmol/L、 HLA-DR( 60.02±12.08) %、 T-CD4+( 422±87) cell/L与第 0天的( 123±59.8) mmoL/L、( 41.22±15.90) %、( 220±54) cell/L间差异有统计学意义( P<0.05),且与对照组的( 34.1±11.8) mmol/L、( 42.06±14.08) %、( 326±69) cell/L间差异有统计学意义( t=1.781、 2.603、 2.527, P<0.05)。治疗组 28 d死亡 9例( 25.0%), VAP发生率为 21.77‰,低于对照组的 10例( 26.3%)( χ2=4.432, P=0.028)、 42.12%( χ2=0.017, P=0.897)。 结论 乌司他丁能改善重症病毒性肺炎患者的免疫功能,降低 VAP发生率,但无法改善预后。 [关键词 ] 重症病毒性肺炎 ;免疫干预 ;乌司他丁 [Abstract] Objective To investigate the clinical efficacy of ulinastatin in immunomodulatory therapy of severe viral pneumonia. Methods the clinical data of patients with severe viral pneumonia admitted to our hospital from January 2017 to December 2019 were retrospectively analyzed, and the effect of ulinastatin on immunity and prognosis of patients was analyzed. Results 74 patients with severe viral pneumonia were included, 19 (25.7%) died; There are 36 patients in the treatment group of 36 patients in the treatment group of 36 patients in the treatment group of 36 patients in the seventh day of CRP (46.2 ± 32.8) mmol / L, HLA-DR (60.02 ± 12.08), t-cd4 + (422 ± 87 ± 87) cell / L on the seventh day and (123 ± 59.8) mmol / L, (41.22 ± 15.90)%, (220 ± 54) cell / L (P < 0.05), and there are statistically significant differences between (34.1 ± 11.8) mmol / L, (42.06 ± 14.08)%, (326 ± 69) cell / L / L of the control group (t = 1.1.1.1.1.1.8) mmol / L, (42.06 ± 14.08 ± 14.08)%, (326 ± 69 781 2.603、 2.527, P<0.05)。 The incidence of VAP in the treatment group was 21.77 ‰, which was lower than that in the control group (26.3%) (χ 2 = 4.432, P = 0.028) and 42.12% (χ 2 = 0.017, P = 0.897). Conclusion Ulinastatin can improve the immune function of patients with severe viral pneumonia, reduce the incidence of VAP, but can not improve the prognosis.
简介:【摘 要】目的:分析CT与MRI诊断乙型肝炎肝硬化继发小肝癌的临床价值。方法:本实验所包含的对象是2019年6月-2020年8月我院收治的90例乙型肝硬化继发小肝癌患者,依照单双数法将患者分为研究组与对照组,每组包含患者45例。对照组患者进行CT扫描,研究组患者进行MRI诊断,对比两组患者诊断敏感度、特异度、准确度,以病理诊断为金标准,分析CT与MRI诊断乙型肝炎肝硬化继发小肝癌的临床价值。结果:对比研究发现,研究组患者敏感度、特异度、准确度均高于对照组患者,组间差异具有显著性特征(P
简介:【摘要】目的 急性脑梗死静脉溶栓治疗桥接血管内介入治疗后应用丁苯酞氯化钠治疗的临床疗效。方法 选取2019年9月-2020年9月在我院治疗的急性脑梗死共60例,按照随机颜色球法分为观察组和参照组,各30例。参照组接受标准治疗,观察组在参照组的基础上应用丁苯酞氯化钠治疗。比对两组患者的治疗效果、神经功能缺损评分。结果 两组患者的有效率对比存在差异,观察组有效率高于参照组,差异明显(P<0.05)。两组患者的神经功能缺损评分对比存在差异,观察组优于参照组,差异明显(P<0.05)。结论 静脉溶栓治疗桥接血管内介入治疗后应用丁苯酞氯化钠效果理想,且能改善患者的神经功能缺损程度,值得推广。
简介: 【摘 要】目的:研究小切口阑尾炎切除术治疗阑尾炎的临床疗效。方法:选取 2018年 12月 -2020年 1月 70例阑尾炎患者作为研究对象,抽取 35例作为观察组,另根据配对原则抽取 35例作为对照组。对照组采用传统切口阑尾切除术,观察组采用小切口阑尾炎切除术。对比手术时间、术中出血量及术后并发症发生率。结果:观察组手术时间短于对照组,术中出血量及术后并发症发生率少于对照组,对比差异有统计学意义( P<0.05)。结论:小切口阑尾炎切除术治疗阑尾炎具有显著效果,可缩短治疗时间,减少术中出血及术后并发症对患者造成的影响,值得临床推广。 【关键词】小切口阑尾炎切除术;阑尾炎;并发症 Objective: To study the clinical effect of small incision appendectomy in the treatment of appendicitis. Methods: 70 cases of appendicitis patients from December 2018 to January 2020 were selected as the research object, 35 cases were selected as the observation group, and 35 cases were selected as the control group according to the matching principle. The control group was treated with traditional incision appendectomy, and the observation group was treated with small incision appendectomy. The operation time, intraoperative blood loss and postoperative complications were compared. Results: the operation time of the observation group was shorter than that of the control group, the intraoperative blood loss and the incidence of postoperative complications were less than those of the control group, the difference was statistically significant (P < 0.05). Conclusion: small incision appendectomy in the treatment of appendicitis has a significant effect, can shorten the treatment time, reduce intraoperative bleeding and postoperative complications on patients, which is worthy of clinical promotion.
简介:【摘要】目的:分析中晚期非小细胞肺癌患者长期服用金福安汤的不良反应发生情况。方法:纳入对象是80例本院治疗的中晚期非小细胞肺癌患者,将病例分成对比组(单独化疗治疗,40例)与研究组(金福安汤+化疗治疗,40例),对比两组治疗期间的疼痛程度、生存质量评分,比较两组骨髓抑制、消化道反应等不良反应发生情况。结果:研究组疼痛评分更低,生存质量更高,与对比组比较有统计学意义(P<0.05);研究组骨髓抑制、消化道反应等不良反应发生率低于对比组,比较有统计学意义(P<0.05)。结论:金福安汤有利于缓解中晚期非小细胞肺癌患者的疼痛程度,提高生活质量,且可改善化疗毒副反应,值得推荐。